Contraindicaciones cardiológicas para la práctica deportiva

  1. Gonzalo Grazioli
  2. Daniel Brotons Cuixart
  3. Fernando Pifarré
  4. María Sanz De la Garza
  5. Silvia Montserrat
  6. Bàrbara Vidal
  7. Carles Miñarro
  8. Ramón Pi
  9. G. Sarquella-Brugada
  10. Josep Gutierrez
  11. Josep Brugada
  12. Marta Sitges Carreño
Revista:
Apunts: Medicina de l'esport
  1. Sitges Carreño, Marta

ISSN: 1886-6581,  0213-3717

Año de publicación: 2017

Volumen: 52

Número: 193

Tipo: Artículo

DOI: 10.1016/J.APUNTS.2016.09.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Apunts: Medicina de l'esport

Objetivos de desarrollo sostenible

Resumen

La muerte súbita en el deporte está causada en la mayoría de ocasiones por enfermedades cardiacas. El objetivo del cribado pre-participativo es poder identificar a los individuos que requieran un tratamiento específico para continuar el deporte o el cese de la práctica deportiva. La evidencia científica actual se basa en recomendaciones de expertos que en algunos casos son controvertidas y en ocasiones poco prácticas. Esta revisión tiene como objetivo dar un enfoque actualizado y pragmático de las recomendaciones en los deportistas con cardiopatía.

Referencias bibliográficas

  • 1. Sharma S, Merghani A, Mont L. Exercise and the heart: The good, the bad, and the ugly. Eur Heart J. 2015; 36: 1445-53, http://dx.doi.org/10.1093/eurheartj/ehv090
  • 2. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009; 119: 1085-92, http://dx.doi.org/10.1161/CIRCULATIONAHA.108.804617
  • 3. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003; 42: 1959-63, http://dx.doi.org/10.1016/j.jacc.2003.03.002
  • 4. Maron BJ, Zipes DP, Kovacs RJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Preamble, principles, and general considerations: A scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015; 132: e256-61, http://dx.doi.org/10.1161/CIR.0000000000000236
  • 5. Pelliccia A, Fagard R, Bjørnstad HH, Vanhees L, Biffi A, Borjesson M, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: A consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005; 26: 1422-45, http://dx.doi.org/10.1093/eurheartj/ehi325
  • 6. Heidbüchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, Delise P, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions. Part I: Supraventricular arrhythmias and pacemakers. Eur J Cardiovasc Prev Rehabil. 2006; 13: 475-84, http://dx.doi.org/10.1097/01.hjr.0000216543.54066.72
  • 7. Heidbüchel H, Corrado D, Biffi A, Hoffmann E, PanhuyzenGoedkoop N, Hoogsteen J, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil. 2006; 13: 676-86, http://dx.doi.org/10.1097/01.hjr.0000239465.26132.29
  • 8. Takken T, Giardini A, Reybrouck T, Gewillig M, HövelsGürich HH, Longmuir PE, et al. Recommendations for physical activity, recreation sport, and exercise training in paediatric patients with congenital heart disease: A report from the Exercise, Basic & Translational Research Section of the European Association of Cardiovascular Prevention. Eur J Cardiovasc Prev Rehabil. 2012; 5: 1034-65, http://dx.doi.org/10.1177/1741826711420000
  • 9. Budts W, Börjesson M, Chessa M, van Buuren F, Trigo Trindade P, Corrado D, et al. Physical activity in adolescents and adults with congenital heart defects: Individualized exercise prescription. Eur Heart J. 2013; 34: 3669-74, http://dx.doi.org/10.1093/eurheartj/eht433
  • 10. Levine BD, Baggish AL, Kovacs RJ, Link MS, Maron MS, Mitchell JH. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 1: Classification of sports: Dynamic, Static, and Impact. A scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2015; 132: e262-6, http://dx.doi.org/10.1161/CIR.0000000000000237
  • 11. Riebe D, Franklin BA, Thompson PD, Ewing Garber CE, Whitfield GP, Magal M, et al. Updating ACSM’s recommendations for exercise preparticipation health screening. Med Sci Sports Exerc. 2015; 47: 2473-9, http://dx.doi.org/10.1249/MSS.0000000000000664
  • 12. Sheikh N, Papadakis M, Ghani S, Zaidi A, Gati S, Adami PE, et al. Comparison of electrocardiographic criteria for the detection of cardiac abnormalities in elite black and white athletes. Circulation. 2014; 129: 1637-49, http://dx.doi.org/10.1161/CIRCULATIONAHA.113.006179
  • 13. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NA, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis. A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015; 132: e273-80, http://dx.doi.org/10.1161/CIR.0000000000000239
  • 14. Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. 2005; 45: 1340-5, http://dx.doi.org/10.1016/j.jacc.2005.02.011
  • 15. Mellwig KP, van Buuren F, Gohlke-Baerwolf C, Bjørnstad HH. Recommendations for the management of individuals with acquired valvular heart diseases who are involved in leisure-time physical activities or competitive sports. Eur J Cardiovasc Prev Rehabil. 2008; 15: 95-103, http://dx.doi.org/10.1097/HJR.0b013e3282ef9973
  • 16. Bonow RO, Nishimura RA, Thompson PD, Udelson JE. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 5: Valvular heart disease. A Scientific Statement from the American Heart Association and American College of Cardiology. Circulation. 2015; 132: e292-7, http://dx.doi.org/10.1161/CIR.0000000000000241
  • 17. Zipes DP, Link MS, Ackerman MJ, Kovacs RJ, Myerburg RJ, Estes NAM. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 9: Arrhythmias and conduction defects. A Scientific Statement from the American Heart Association and American College of Cardiology. Circulation. 2015; 132: e315-25, http://dx.doi.org/10.1161/CIR.0000000000000245
  • 18. Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: The Cardiac Channelopathies. A Scientific Statement from the American Heart Association and American College of Cardiology. Circulation. 2015; 32: e326-9, http://dx.doi.org/10.1161/CIR.0000000000000246
  • 19. Van Hare GF, Ackerman MJ, Evangelista JAK, Kovacs RJ, Myerburg RJ, Shafer KM, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 4: Congenital Heart Disease. A Scientific Statement from the American Heart Association and American College of Cardiology. Circulation. 2015; 132: e281-91, http://dx.doi.org/10.1161/CIR.0000000000000240
Fuente de los datos: Dialnet